Strategy Asset Managers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Strategy Asset Managers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,270	Closed	-$590K	–	278
2021 Q4	$590K	Buy	5,270 +1,335	+34%	+$161K	0.15%	118
2021 Q3	$495K	Buy	3,935 +157	+4%	+$20.2K	0.11%	155
2021 Q2	$512K	Sell	3,778 -345	-8%	-$45.4K	0.11%	149
2021 Q1	$559K	Buy	4,123 +201	+5%	+$30.1K	0.13%	129
2020 Q4	$552K	Buy	3,922 +210	+6%	+$26.9K	0.13%	127
2020 Q3	$413K	Buy	3,712 +202	+6%	+$22.6K	0.11%	150
2020 Q2	$393K	Buy	3,510 +275	+9%	+$27.1K	0.11%	150
2020 Q1	$250K	Buy	+3,235	New	+$286K	0.08%	164
2019 Q2	–	Sell	-185	Closed	-$17K	–	203
2019 Q1	$17K	Buy	+185	New	+$15.7K	﹤0.01%	183

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Strategy Asset Managers's XBI Position: Q1 2022 in Review

Strategy Asset Managers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 5,270 shares — an estimated $590K sold.

Strategy Asset Managers first reported a position in XBI in Q1 2019 and held it in 9 quarters. The position peaked at $590K in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Strategy Asset Managers reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Strategy Asset Managers sold 5,270 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $590K.
Strategy Asset Managers first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and held it in 9 quarters.
Strategy Asset Managers's State Street SPDR S&P Biotech ETF position peaked at $590K in Q4 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Strategy Asset Managers's 13F filing for Q1 2022, filed 11 Apr 2022.